

8.

DERMATOLOGY

CHAPTER

2019 NOVEL CORONA- VIRUS (COVID-19) INDUCED CUTANEOUS VASCULITIS

Nazlı CAF¹

BACKGROUND

Novel Coronavirus disease 2019 (COVID-19) is a viral disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which leads to severe respiratory diseases such as pneumonia and pulmonary deterioration, was first reported in Wuhan, China (1).

The agent is enveloped positive single-stranded large RNA virus. The transmission of the viral infection is fast; within a few months of the index patient, SARS-CoV-2 had spread worldwide(2). The disease has been declared as a pandemic by the World Health Organization (WHO). SARS-CoV-2 mainly presents with respiratory system involvement but multisystemic symptoms are also observed (2). COVID-19 symptoms resemble Severe Acute Respiratory Syndrome Coronavirus which was emerged in 2002 (SARS-CoV).

The most common COVID-19 symptoms are dry cough, fever, and malaise. Other common symptoms are headache, diarrhea, loss of sense of smell, and taste. People having chronic diseases such as hypertension, diabetes mellitus, and coronary artery disease are more vulnerable to COVID-19 (3). COVID-19 affects multiple organs and indeed the largest organ of the body: The skin.

¹ MD, Dermatologist, Istanbul Basaksehir Cam and Sakura City Hospital, Department of Dermatology
Email: naslicaf@hotmail.com

REFERENCES

1. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). *J Microbiol Biotechnol*. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011. PMID: 32238757.
2. Mousa Suhail Abu Ghoush, Mahfoud El. Bashari, Amani Alzaabi and Mohammed Aboelnaga. COVID-19 Vasculitis: A Case Report with Complicated Course. *American Journal of Medical Case Reports*. 2020; 8(11):428-430. doi: 10.12691/AJMCR-8-11-13
3. Vellas, C et al. "COVID-19, Virology and Geroscience: A Perspective." *The journal of nutrition, health & aging* vol. 24,7 (2020): 685-691. doi:10.1007/s12603-020-1416-2
4. Gupta, A., Madhavan, M.V., Sehgal, K. et al. Extrapulmonary manifestations of COVID-19. *Nat Med* 26, 1017–1032 (2020). <https://doi.org/10.1038/s41591-020-0968-3>
5. Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. *Br J Dermatol*. 2020 Sep;183(3):431-442. doi: 10.1111/bjd.19264. Epub 2020 Jul 5. PMID: 32479680; PMCID: PMC7300648.
6. Hedou, M et al. "Comment on 'Cutaneous manifestations in COVID-19: a first perspective' by Recalcati S." *Journal of the European Academy of Dermatology and Venereology : JEADV* vol. 34,7 (2020): e299-e300. doi:10.1111/jdv.16519
7. Belizna, Cristina C et al. "Infection and vasculitis." *Rheumatology (Oxford, England)* vol. 48,5 (2009): 475-82. doi:10.1093/rheumatology/kep026
8. Becker, Richard C. "COVID-19-associated vasculitis and vasculopathy." *Journal of thrombosis and thrombolysis* vol. 50,3 (2020): 499-511. doi:10.1007/s11239-020-02230-4
9. Amraei, Razie, and Nader Rahimi. "COVID-19, Renin-Angiotensin System and Endothelial Dysfunction." *Cells* vol. 9,7 1652. 9 Jul. 2020, doi:10.3390/cells9071652
10. Haq, S.A. and Pagnoux, C. (2019), Infection-associated vasculitides. *Int J Rheum Dis*, 22: 109-115. doi:10.1111/1756-185X.13287
11. Novak N, Peng W, Naegeli MC, Galvan C, Kolm-Djamei I, Brügggen C, Cabanillas B, Schmid-Grendelmeier P, Catala A. SARS-CoV-2, COVID-19, skin and immunology - What do we know so far? *Allergy*. 2020 Jul 13:10.1111/all.14498. doi: 10.1111/all.14498. Epub ahead of print. PMID: 32658359; PMCID: PMC7404682.
12. Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. *Neth J Med*. 2012 Jan;70(1):12-7. PMID: 22271809.
13. Hussein, M. R. A. (2015). *Drug-induced skin reactions: a pathologist viewpoint. Cutaneous and Ocular Toxicology*, 35(1), 67–79. doi:10.3109/15569527.2015.1015725
14. Girijala RL, Siddiqi I, Kwak Y, Wright D, Patel DB, Goldberg LH. Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation. *J Drugs Dermatol*. 2019 Feb 1;18(2):207-209. PMID: 30811149.
15. Manzo C, Pollio N, Natale M. Sweet's Syndrome Following Therapy with Hydroxychloroquine in a Patient Affected with Elderly-Onset Primary Sjogren's Syndrome. *Medicines (Basel)*. 2019 Nov 15;6(4):111. doi: 10.3390/medicines6040111. PMID: 31731586; PMCID: PMC6963767.
16. Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? *Clin Mol Allergy*. 2020 Oct 6;18:19. doi: 10.1186/s12948-020-00133-6. PMID: 33033459; PMCID: PMC7537980.
17. Wolstencroft, Paige W et al. "Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis." *JAMA dermatology* vol. 154,10 (2018): 1199-1203. doi:10.1001/jamadermatol.2018.2549
18. Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. *Cutis*. 2016 Mar;97(3):212-6. PMID: 27023083.

19. Leckie MJ, Rees RG. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 Apr;41(4):473-4. doi: 10.1093/rheumatology/41.4.473. PMID: 11961185.
20. Sharma, A. N., Mesinkovska, N. A., & Paravar, T. (2020). *Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review*. *Journal of the American Academy of Dermatology*. doi:10.1016/j.jaad.2020.04.024
21. Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. *J Med Case Rep*. 2014 Oct 8;8:332. doi: 10.1186/1752-1947-8-332. PMID: 25297051; PMCID: PMC4196465.
22. Trevisi, P., Patrizi, A., Neri, I., & Farina, P. (1994). Toxic pustuloderma associated with azithromycin. *Clinical and Experimental Dermatology*, 19(3), 280–280. doi:10.1111/j.1365-2230.1994.tb01191.x
23. Aihara, Y., Ito, S., Kobayashi, Y., & Aihara, M. (2004). *Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection*. *Allergy*, 59(1), 118–118. doi:10.1046/j.1398-9995.2003.00336.x
24. Umeshchandra, C.H., et al. "Azithromycin induced fixed drug eruption." *Journal of Evolution of Medical and Dental Sciences*, vol. 3, no. 15, 2014, p. 4052+. *Gale OneFile: Health and Medicine*, . Accessed 14 Oct. 2020.
25. Odemis E, Kalyoncu M, Okten A, Yildiz K. Azithromycin-induced leukocytoclastic vasculitis. *J Rheumatol*. 2003 Oct;30(10):2292. PMID: 14528532.
26. Daye, Munise. "A case report of Baboon Syndrome due to azithromycin." *Our Dermatology Online* 10 (2019): 173-175.
27. Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. *Antivir Ther*. 2004 Apr;9(2):187-95. PMID: 15134180.
28. Klejtman, T. "Skin and COVID-19." *Journal de medecine vasculaire* vol. 45,4 (2020): 175-176. doi:10.1016/j.jdmv.2020.06.001